J&J Ordered To Pay $8 Bln In Case Over Male Breast Growth On Anti-psychotic Drug
Wednesday, 9 October 2019 () A Philadelphia jury ordered that Johnson & Johnson (JNJ) must pay $8 billion in punitive damages to a man who claimed the company failed to warn that boys using its Risperdal anti-psychotic drug could grow breasts.
Drugmakers were in the spotlight Wednesday as GSK recalls Zantac after U.S. regulators found probable cancer-causing impurities in the drug. Also in the U.S.: a jury says Johnson & Johnson must pay $8 billion in a case over male breast growth linked to Risperdal. David Pollard reports.
A Philadelphia jury on Tuesday awarded $8 billion in punitive damages against Johnson & Johnson and one if its subsidiaries over a drug the companies made that the plaintiff's attorneys say is linked..
Johnson & Johnson (NYSE:JNJ) has been ordered to pay $8 billion in punitive damages to a man who claims the company failed to warn him that antipsychotic drug... Proactive Investors Also reported by •NYTimes.com •BBC News •Independent •CBS News